Seres Therapeutics, Inc. (MCRB)
Health Care ยท Pharmaceutical Preparations
Seres Therapeutics, Inc. (MCRB) is listed on Nasdaq, where its shares have traded since June 26, 2015. SentiSense covers Seres Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Richard N. Kender is its chief executive officer. The company reports 66 employees, and its corporate website is www.serestherapeutics.com.
About Seres Therapeutics, Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
Latest reported results
Seres Therapeutics, Inc. reported revenue of $736.0 thousand for Q2 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 34 institutions reported holding MCRB, with 2.3 million shares worth $17.9 million in aggregate. The largest reported holders were Flagship Pioneering, Vanguard and Marshall Wace. Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
More on MCRB
- MCRB sentiment: whether news and social coverage of Seres Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- MCRB ownership: all 34 reporting institutions, plus insider and congressional trades.
- MCRB financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for Seres Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Seres Therapeutics, Inc. do?
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates.
What sector is MCRB in?
SentiSense classifies Seres Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does MCRB stock trade?
Seres Therapeutics, Inc. (MCRB) is listed on Nasdaq, where its shares have traded since June 26, 2015.
Who is the CEO of Seres Therapeutics, Inc.?
Richard N. Kender is the chief executive officer of Seres Therapeutics, Inc..